PP
Propanc Biopharma, Inc.
PPCB · NASDAQ
$0.63 +6.63% (+$0.04)
1M -53.31%
Market Cap $1.37M
P/E Ratio -
Div. Yield -
ROE 148.23%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.14x
P/E N/A
P/FFO N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 161.15%
Asset turnover 0.00x
ROE 148.23%
Debt
69 /100
Low Debt/Equity 0.16x
Int. coverage -26.93x
Current ratio 2.37x
Stability
44 /100
Moderate Beta 3.33x
Profitable years 0
EPS volatility 1.31%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PPCB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James Nathanielsz
Employees
2
Headquarters
Camberwell